



# Prevention NOW!

February 2021 - Issue 65



The [Conference on Retroviruses and Opportunistic Infections](#) (CROI) takes place virtually from March 6-10. Live interactive and engaging sessions will be featured each day, along with on-demand content. HPTN researchers will present six abstracts (one oral; five Scientific Spotlights™) covering [HPTN 052](#), [HPTN 071](#), and [HPTN 083](#). Presentations will be available online after their initial presentation at [hptn.org/presentedresearch](http://hptn.org/presentedresearch).

[View Schedule of HPTN Presentations and Sessions](#)



HPTN  
HIV Prevention  
Trials Network

*Our Year  
In Review*

2020

We look back at 2020, a year that brought many unexpected challenges due to the ongoing COVID-19 pandemic, as well as new HIV prevention research findings.

## Shoutouts

Congratulations to Dr. Mina Hosseinipour, [HPTN 084](#) protocol co-chair, professor of medicine at the University of North Carolina (UNC) at Chapel Hill School of Medicine, and scientific director of UNC Project-Malawi in Lilongwe, Malawi. UNC leadership recently awarded her with a 2021 Distinguished Teaching Award for post-baccalaureate instruction. Since 2005, Dr. Hosseinipour has hosted and mentored more than 100 young researchers, providing them with the clinical and global research experience necessary to advance their academic careers in global health.





The HPTN LOC welcomes Jasmine Sanders, our first intern, as part of a newly established internship program between [FHI 360](#) and North Carolina Central University, an historically Black university located just a short distance from our headquarters in Durham, NC. Jasmine is working toward her bachelor's degree in public health education. She will support us by analyzing and optimizing the HPTN website and working on HPTN 096 branding and video creation projects. We are excited to have Jasmine join our HPTN team and look forward to her skilled contributions to our HIV prevention activities.

## Network Member Spotlight

Dr. Steven Shoptaw is protocol co-chair for [HPTN 094](#), a professor in the University of California at Los Angeles (UCLA) departments of Family Medicine and Psychiatry and Biobehavioral Sciences, and professor (Hon) in psychiatry at the University of Cape Town. He energetically leads research, clinical, and policy efforts that bring novel and high-impact strategies and delivering culturally competent care and prevention for persons affected by addictions and HIV. Mentoring emerging clinical and research scholars worldwide is a strong passion as well. Recent examples include involvement in the HPTN Scholars program and the newly minted HPTN Bridge program. Dr. Shoptaw also maintains a limited clinical psychology practice at UCLA, treating severe substance use and mental health disorders.



[Read More](#)

## Awareness Days



## Hot Off The Press

Zeziulin O, Mollan KR, Shook-Sa BE, Hanscom B, Lancaster KE, Dumchev K, Go VF, Chu VA, Kiriazova T, Syarif Z, Dvoryak S, Reifeis SA, Hamilton E, Sarasvita R, Rose S, Richardson P, Clarke W, Latkin CA, Metzger DS, Hoffman IF, Miller WC. [Depressive symptoms and use of HIV care and medication-assisted treatment among people with HIV who inject drugs](#). AIDS. 2021 Mar 1;35(3):495-501.

Mgodi NM, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E, Garnett P, Shava E, Mukwekwerere PG, Kochar N, Marshall K, Rudnicki E, Juraska M, Anderson M, Karg C, Tindale I, Greene E, Luthuli N, Baepanye K, Hural J, Gomez Lorenzo MM, Burns D, Miner MD, Ledgerwood J, Mascola JR, Donnell D, Cohen MS, Corey L; and the HVTN 703/HPTN 081 Team. [A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: baseline findings](#). J Acquir Immune Defic Syndr. 2021 Feb 11.

Edupuganti S, Mgodhi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, Cohen MS, Corey L; HVTN 704/HPTN 085 study group. [Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody](#). J Acquir Immune Defic Syndr. 2021 Feb 11.

Mbichila T, Kumwenda G, Yola N, Karim QA, Tchelidze T, Lau J, Buchholz S, Lehnert R, Molina JM, Mayer K, Miller V. [Commentary title: COVID-19 Research, Africa, and Global Health](#). J Virus Erad. 2021 Feb 3;7(1):100030.

Bhattacharya D, Guo R, Tseng CH, Emel L, Sun R, Chiu SH, Stranix-Chibanda L, Chipato T, Mohtashemi NZ, Kintu K, Manji KP, Moodley D, Thio CL, Maldonado Y, Currier JS. [Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV](#). Pediatr Infect Dis J. 2021 Feb 1;40(2):e56-e61.

Rennie S, Chege W, Schrupf L, Luna F, Klitzman R, Moseki E, Brown B, Wakefield S, Sugarman J. [HIV prevention research and COVID-19: putting ethics guidance to the test](#). BMC Medical Ethics. 2021 Jan 25.



---

What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at [news@hptn.org](mailto:news@hptn.org).

*Copyright © 2021 The HIV Prevention Trials Network, All rights reserved.*